News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 04 - 29

Shensi Bio's Ultra-Long-Acting Recombinant Factor VIII FRSW117 NMPA Application Accepted

Shensi Bio announced today (April 29, 2026) that its independently developed Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (project code: FRSW117) has been submitted for marketing authorization to the National Medical Products Administration (NMPA) and has officially been accepted for review. FRSW117 is a world-first, ultra-long-acting recombinant Factor VIII product that combines two half-life extension technologies—Fc fusion and PEGylation. It is intended for routine prophylactic treatment, on-demand replacement therapy, and perioperative bleeding manage...

浏览次数：5

查看详情>>

发布时间: 2026 - 04 - 28

Ef Capital CEO Zhu Pai Receives the "2026 Top 40 Under 40 Best Direct Investment Fund Young Investor

Today, the FOF Research Center officially released its "2026 40U40 Outstanding Young Investors" rankings. Zhu Pai, CEO of Ef Capital, has been honored with the "2026 Top 40 Under 40 (40U40) Best Direct Investment Fund Young Investor" award.On the occasion of the upcoming Youth Day (May 4th), the FOF Research Center, supported by comprehensive data and in-depth research analysis, unveiled this significant ranking designed to encourage dedicated young professionals who quietly contribute to the private equity investment industry. Industry consensus traditionally holds that ta...

浏览次数：4

查看详情>>

发布时间: 2026 - 04 - 27

Highlands Pharma Reports Positive Phase III Data for RA Drug Ginositinib (TLL-018)

Highlands Pharmaceuticals today announced positive topline results from its Phase III clinical trial ("TARA Study") evaluating Ginositinib, an oral small-molecule JAK1/TYK2 inhibitor， for the treatment of active rheumatoid arthritis (RA). The study met its primary and all secondary efficacy endpoints, demonstrating statistically superior outcomes compared to the positive control drug Tofacitinib (Xeljanz), along with a favorable safety and tolerability profile. This marks the first registrational study globally to use another JAK inhibitor as a positive control and achieve superior e...

浏览次数：5

查看详情>>

发布时间: 2026 - 04 - 24

EFUNG Capital Secures Multiple Annual Honors at the ChinaVenture Awards

Today, at the highly anticipated "ChinaVenture 20th Annual Investment Summit · Annual Conference," the prestigious ChinaVenture Awards list was officially unveiled. Leveraging its deep expertise in the healthcare industry, EFUNG Capital swept multiple significant institutional and individual awards.EFUNG Capital was honored with: ChinaVenture 2025 Top 50 Best RMB-denominated Venture Capital Firms, ChinaVenture 2025 Top 20 Medical Device Investment Institutions in the Healthcare Sector, and ChinaVenture 2025 Top 100 Best Venture Capital Firms.At the same time, Mr. Zhu Pai, CEO of...

浏览次数：3

查看详情>>